Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gefitinib or Docetaxel · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Gefitinib or Docetaxel | DRUG | - |
Inclusion Criteria: * You are "histologically" or "cytologically" confirmed to have recurrent or metastatic NSCLC * You have been treated with chemotherapy including platinums for NSCLC. Exclusion Criteria: * You have received treatment for non-small lung cancer within 4 weeks before your partici...
Top 20 of 90 competitors
Gefitinib is an oral small molecule developed by AstraZeneca PLC (ticker AZN) for non-small cell lung cancer. It is being studied in a Phase 3 second-line setting in Japan. Gefitinib is an investigational therapy in this program and is not described as approved for this use.
Gefitinib targets EGFR, the epidermal growth factor receptor. It acts as an EGFR inhibitor, a small molecule that blocks EGFR signaling. This mechanism underlies its development in non-small cell lung cancer, where EGFR-driven tumor growth is relevant to treatment.
Gefitinib is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor associated with the Phase 3 program in non-small cell lung cancer, including the Japanese second-line study of gefitinib.
Gefitinib is in Phase 3 development for non-small cell lung cancer. The program includes one completed Phase 3 trial with 484 enrolled patients. Gefitinib is investigational in this setting and is not described as approved for this indication.
Gefitinib has been studied in NCT00252707, titled Iressa 2nd Line Phase III Study in Japan. This completed Phase 3 trial enrolled 484 patients with non-small cell lung cancer in Japan. It was randomized, was not double blind, and used an uncontrolled design.
No. Gefitinib and docetaxel are different drugs. Gefitinib is an EGFR inhibitor small molecule developed by AstraZeneca PLC for non-small cell lung cancer. Docetaxel is a separate agent. The two names refer to distinct therapies and should not be used interchangeably.